Key facts
- Notable investors include Guangdong Technology Financial Group, Chengdu Bio-Town Investment, China Life Private Equity, SDIC Venture Capital, State Development and Investment Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Glotope Advanced Pharmaceutical Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Glotope Advanced Pharmaceutical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Glotope Advanced Pharmaceutical Technology
Manufacturer of radiopharmaceuticals intended for nuclear medicine applications. The company offers radionuclide synthesis and labeling, screening and validation, pharmacokinetics imaging, GMP manufacturing, clinical and commercial supply distribution, cassette and kit provision, IRC services, and quality control systems, thereby supporting efficient drug development, regulatory approval, and global delivery of targeted radiopharmaceutical therapies.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Employees
- 3
- Website
- glotope.com/
- Ownership
- Privately Held (backing)
Glotope Advanced Pharmaceutical Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Glotope Advanced Pharmaceutical Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Glotope Advanced Pharmaceutical Technology in its N-PORT filings yet. We sweep new filings monthly.